Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
Author:
Funder
Welch Foundation
CPRIT
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Link
https://link.springer.com/content/pdf/10.1007/s40259-022-00529-7.pdf
Reference554 articles.
1. Von Behring E, Kitasato S. Ueber das Zustandekommen der Diphtherie-Immunitat and der Tetanus-Immunitat bei Thieren. Dtsch Med Wochenschr. 1890;16:1113–4 (in German).
2. Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis. 1995;21(1):150–61. https://doi.org/10.1093/clinids/21.1.150.
3. Berry JD, Gaudet RG. Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology. N Biotechnol. 2011;28(5):489–501. https://doi.org/10.1016/j.nbt.2011.03.018.
4. Salazar G, Zhang N, Fu TM, An Z. Antibody therapies for the prevention and treatment of viral infections. NPJ Vaccines. 2017;2:19. https://doi.org/10.1038/s41541-017-0019-3.
5. Kumar D, Gauthami S, Bayry J, Kaveri SV, Hegde NR. Antibody therapy: From diphtheria to cancer, COVID-19, and beyond. Monoclon Antib Immunodiagn Immunother. 2021;40(2):36–49. https://doi.org/10.1089/mab.2021.0004.
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19;Expert Opinion on Biological Therapy;2024-08-02
2. Predicting the risk of primary Sjögren's syndrome with key N7-methylguanosine-related genes: A novel XGBoost model;Heliyon;2024-05
3. Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19;Frontiers in Immunology;2024-04-17
4. Viral Epitope Scanning Reveals Correlation between Seasonal HCoVs and SARS-CoV-2 Antibody Responses among Cancer and Non-Cancer Patients;Viruses;2024-03-13
5. Next-generation treatments: Immunotherapy and advanced therapies for COVID-19;Heliyon;2024-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3